Mylan Says PPI Formulary Impact Unclear As Omeprazole Options Increase
This article was originally published in The Tan Sheet
Executive Summary
Prescription proton pump inhibitor manufacturers are becoming increasingly wary of the effect Prilosec OTC will have on the formulary status of generic offerings
You may also be interested in...
Prilosec OTC Formulation Targeted In Mylan Labs Suit
Mylan Laboratories' lawsuit against Procter & Gamble over the formulation of Prilosec OTC is the most recent in a string of challenges for the over-the-counter heartburn medication
Generic PPIs Look For Long-Term Formulary Benefit From Prilosec OTC
Price pressures caused by the availability of Procter & Gamble's Prilosec OTC may offer potential upsides for generic omeprazole offerings regarding favorable formulary status, according to insurers
Novartis Omeprazole Offering, Wellpoint, Prilosec OTC Pressure PPI Prices
Novartis' entrance into the OTC loratadine market in March could set a precedent for the firm to make a similar move with the proton pump inhibitor omeprazole